Skip to content
Investing

Kraig Biocraft Laboratories Profile: Spider Silk From Silkworms, Still Before Revenue

Kraig Biocraft Laboratories breeds silkworms that spin spider silk and farms them in Vietnam. It has begun shipping yarn but reported no revenue in the first half and carries a going concern warning.

A worker tending silkworms on mulberry leaves on rearing racks under green netting, published with the 5 October 2026 production release
Photo: Kraig Biocraft Laboratories

Kraig Biocraft Laboratories has spent years engineering silkworms to spin spider silk, a fibre prized for strength and toughness. In the past two months it has shipped its first commercial yarn order and run all three of its rearing centres in Vietnam, but its latest accounts show no revenue, a large deficit and a going concern warning.

What the company does

Kraig Biocraft Laboratories, known as Kraig Labs, is a US biotechnology company quoted on the OTCQB under the ticker KBLB. Its research headquarters is a leased 5,000-square-foot site in Lansing, Michigan, and its press releases are datelined Ann Arbor.

The company's technology is a genetically engineered silkworm that carries key spider silk proteins. The idea is to use an insect the silk industry already rears in large numbers to produce a recombinant spider silk.

Production takes place in Vietnam through its subsidiary Prodigy Silk, which took over production work after an earlier subsidiary, Prodigy Textiles, was dissolved in January 2026. The company leases facilities and land in Lam Dong province.

Kim Thompson is the founder and chief executive.

Kraig Biocraft Laboratories: share price, chart and news

Two masked laboratory technicians working at microscopes, published with the 12 October 2026 investment licence release.
Two masked laboratory technicians working at microscopes, published with the 12 October 2026 investment licence release. Photo: Kraig Biocraft Laboratories

From the lab to first sales

Kraig has issued a stream of updates since late summer. All are company statements, and few include figures that can be checked.

Recent company announcements

  • 24 August: silk output up more than 30% in what it calls its most technically challenging season; it later said this beat a June cycle of nearly 2.5 tonnes of cocoons
  • 24 September: completion of what it calls a functional and living atlas gene library
  • 29 September: first commercial order of spider silk yarn shipped to an unnamed performance sports brand
  • 5 October: full production at all three rearing centres, run on staggered cycles
  • 12 October: filing for an expanded investment licence for Prodigy Silk, with no amount disclosed
  • 26 October: a performance yarn development programme, and samples sent to an unnamed developer of yarn spinning equipment that has worked with aerospace manufacturers
  • 2 November: an early-stage programme to test diet additives that could raise spider silk protein output

The yarn order matters most, because it is the first commercial sale of its yarn that the company has reported. But Kraig disclosed no quantity, price or customer name, and Thompson said the volume was small by design.

The company has said it intends to pursue several commercial paths, including partnerships with brands, textile mills and manufacturers, and its own apparel work. "Spider silk is a material that will earn its place through performance," Thompson said in October.

The latest numbers and how Kraig funds itself

Kraig's most recent quarterly report, filed with the US Securities and Exchange Commission on 13 August, covers the six months to 30 June 2026.

Results, six months to 30 JuneFigure
Revenue, 2026$0
Operating expenses, 2026$1,528,933
Net loss, 2026$1,852,255
Net loss, same period of 2025$1,326,166
Balance sheet at 30 June 2026Figure
Cash and cash equivalents$3,391,646
Total assets$4,271,792
Total liabilities$11,022,908
Stockholders' deficit$6,751,116
Working capital deficiency$7,326,899
Class A shares outstanding (13 August)1,115,334,070

Second-quarter net loss was $909,535, against $726,133 a year earlier. In the first half, general and administrative costs were $869,947, the chief executive's salary $387,219, professional fees $140,697 and research and development $131,070.

The company also holds 110 ounces of gold bullion, carried at a fair value of $440,652 at 30 June.

Funding at a glance

  • $10m maximum share sales under its standby equity agreement
  • $2.77m raised by selling 25.4m shares in the first half
  • $1.49m note payable to the founder, due on demand

Kraig pays its way mainly by selling new shares. Under a standby equity purchase agreement signed in January 2025, it can sell up to $10m of common stock to an investor. In the first half of 2026 it sold 25,364,093 shares for $2,772,547, after raising $1,925,702 this way in all of 2025.

It also owes money to its founder. The 10-Q lists a $1,492,000 note payable to the founder and chief executive at 3% interest, unsecured and due on demand, and $8.77m of accounts payable and accrued expenses owed to a related party.

There were also 58.3 million warrants and 37.5 million options outstanding at 30 June, which could add further shares if exercised.

Main risks

The filing states that the working capital and stockholders' deficiencies, together with cash used in operations, raise substantial doubt about the company's ability to continue as a going concern. That is the clearest risk: Kraig needs outside money to keep operating.

Dilution follows from that. Each share sale under the equity agreement adds to a share count already above 1.1 billion, and the outstanding warrants and options add more.

The commercial case is unproven. The company has shipped a small first order, but has not shown repeat orders, prices or margins, and it has not published independent test data on its yarn.

Production depends on farming living silkworms in Vietnam, which brings seasonal, biological and country risks, as well as reliance on licences there. Shares quoted on the OTCQB can also trade thinly and move sharply.

What to watch next

EventExpected timing
10-Q for the quarter to 30 September 2026Mid-November 2026
Any revenue from yarn sales in its accountsNext quarterly reports
Follow-on orders from the sports brand pilotNo date given
Outcome of the expanded investment licence filingNo date given
Results from the diet additive programmeNo date given

The September-quarter filing will show whether the first yarn shipment produced any revenue and how much cash remained after the summer's production push.

Sources

Related stories

Business

Kraig Biocraft Laboratories Ships Its First Commercial Spider Silk Yarn Order

Kraig Biocraft Laboratories has shipped its first commercial order of spider silk yarn to an unnamed sports brand, but gave no volume or price and reported no revenue in the first…

Investing

Viking Therapeutics Investor Profile: VK2735, Two Phase 3 Programmes and $960m of Cash

Viking Therapeutics is testing obesity drug VK2735 in Phase 3 as a weekly injection and a daily pill. It had $960m of cash at the end of September but lost $183.2m in the third…

Investing

Novavax Investor Profile: Sanofi Royalties, the Matrix-M Adjuvant and $627m of Cash

Novavax now earns most of its money from partners led by Sanofi. It ended September with $627m of cash and $292.1m of long-term debt; its numbers, milestones, risks and dates to…

Investing

NANO Nuclear Energy Investor Profile: KRONOS, $580m of Cash and a Long Road to Revenue

NANO Nuclear Energy is licensing its KRONOS microreactor in Illinois and building fuel and transport units. It held about $580m of cash in June, but its first reactor is not due…

Investing

Aya Gold & Silver Corrects Q3 Cash Costs to $14.28 an Ounce After Silver Double Count

Aya Gold & Silver refiled its Q3 MD&A after silver in transit was deducted twice. Zgounder ounces sold rise to 1,392,478 and cash costs fall to $14.28 from $15.51. Revenue and…

Investing

FDA Rejects Summit's Lung Cancer Drug Ivonescimab Over Phase 3 Survival Miss

The FDA has rejected Summit Therapeutics' lung cancer drug ivonescimab, saying slower tumour growth in the phase 3 HARMONi trial was not enough without a clear gain in survival.

Investing

Red Cat Withdraws Its $150m to $180m 2026 Revenue Target After $11.8m Third Quarter

Red Cat Holdings has withdrawn its $150m to $180m revenue target for 2026 after third-quarter sales of $11.8m, blaming slower defence funding. Its quarterly net loss more than…

Investing

Berkshire Reveals $689m Bending Spoons Stake, Doubles Lennar and Trims Bank of America Again

Berkshire Hathaway's third-quarter 13F shows a new Bending Spoons stake worth $689m, a doubled Lennar holding and 27.5 million more Bank of America shares sold, while Apple stayed…